Each year, hundreds of thousands of people suffer from spinal cord injury. In addition, poor medical care and the lack of availability of effective treatments contribute to an increase in SCI patient mortality and disability. With rising numbers of workplace accidents, road accidents, and other medical conditions, the global SCI therapeutics market is anticipated to grow at a Compound annual growth rate (CAGR) of 17.84% to reach US$9.61 billion by 2028.
There is a pressing need to create novel therapeutics to treat SCI due to the exorbitant cost of spinal surgery procedures and related healthcare costs. In parallel, the global exosome market is estimated to grow at a CAGR of more than 34% between 2022 and 2030, reaching a market value of around USD 2,273 million by 2030.